Famed Obesity Drug Maker Novo Nordisk Inks Collaborations For Cardiometabolic Diseases
Novo Nordisk A/S (NYSE: NVO), Omega Therapeutics Inc (NASDAQ: OMGA), and Cellarity Inc.
Lexaria’s Patented Technology Improved The Oral Performance Of The Rybelsus-Branded GLP-1 Drug Semaglutide
Final results from a human pilot study show DehydraTECHTM-powered semaglutide outperforms Rybelsus®:Sustained higher levels of semaglutide in blood;Better blood glucose control;Faster achievement of peak drug
Silo Pharma Concludes First Phase of Dose-Ranging Study Of Intranasal Treatment For Post Traumatic Stress Disorder
Thursday, Silo Pharma Inc (NASDAQ: SILO) provided an update on its previously announced dose-ranging study of SPC-15, a targeted prophylactic treatment for post-traumatic stress disorder (PTSD).
BriaCell Images Confirm Robust Anti-Tumor Activity In Patient With “Eye-Bulging” Metastatic Breast Cancer
Significant reduction of metastatic breast cancer tumor behind-the-eye after only 3 cycles Powerful anti-tumor response associated with reduction in proptosis (eye-bulging) and reduced ocular painHeavily
Cardio Diagnostics Holdings, Inc. Unveils Groundbreaking Employer Cardiovascular Disease Risk Intelligence Platform, HeartRisk
HeartRisk™Empowers Employers Who Adopt Cardio Diagnostics' Solutions to Proactively Combat Cardiovascular Disease in Their Workforce and Mitigate Business RisksCardio Diagnostics Holdings, Inc. (NASDAQ:CDIO), an
Reviva Provides Corporate And Program Updates And Highlights Key Upcoming Milestones
– Schizophrenia late-stage clinical program advances with positive topline Phase 3 data, successful ongoing enrollment in open label extension (OLE) trial, and positive drug-drug interaction data supporting a
IN8bio Highlights Recent Company Accomplishments And Outlines 2024 Pipeline Goals
Presented positive data showing continued durable complete remissions (CR) achieved in 100% of evaluable leukemia patients in Phase 1 investigator-sponsored trial of INB-100 at the 65th American Society of Hematology
4DMT Highlights Recent Clinical Pipeline Progress, Near-Term Milestones And Organizational Updates; Ending 2023 With $300M In Estimated Cash, Financial Runway Guidance Unchanged And Cash Expected To Be Sufficient To Fund Operations Into H1 2026
Poised for multiple meaningful catalysts in 2024 driven by strong clinical progress across large market programs in wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and cystic fibrosis
Viracta Therapeutics Provides Clinical Update And Outlook For 2024
Speed to market strategy for Nana-val in patients with relapsed or refractory EBV+ peripheral T-cell lymphoma supported by complete enrollment of Stage 1, complete enrollment of Stage 2 anticipated in Q1 2024 and
First Patient Dosed In Trial Evaluating Efti And The Anti-PD-L1 Therapy BAVENCIO In Metastatic Urothelial Cancer
Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces that the first